secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001628280-23-036397
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology Q3 net loss $163.4M; revenue down 99% YoY on sotrovimab sales decline
--------------------------------------------------------------------------------

- Net loss of $163.4M ($1.22/share) vs net income of $175.3M ($1.32/share) in Q3 2022.
- Total revenue $2.6M, down 99.3% from $374.6M a year ago due to lower sotrovimab sales.
- Cash, equivalents and investments $1.7B; $67M paid to GSK for excess sotrovimab supply.
- Secured ~$50M in new BARDA funding to advance next-gen COVID-19 mAb VIR-7229 through Phase 1.
- Appointed Jennifer Towne, Ph.D., as EVP and Chief Scientific Officer, effective Nov 6, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/0001628280-23-036397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/vir-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-036397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer